How are biosimilars and generic alternatives affecting your plan management strategy?

NEW BLOG

The Impact of Biosimilars and Generic Alternatives on Specialty Management

As healthcare plans adapt to the evolving landscape, they are implementing strategies to effectively manage biosimilars and generic alternatives, thereby benefiting patients and impacting drug rebates. Read more.

INDUSTRY NEWS

• Almost $20B spent in 2022 by providers pursuing claim delays and denials.
• Payers and providers divided what Congress should focus on with ERISA.
• Self-funded plans continue to reign supreme for employers.
• The most expensive gene therapy has been officially priced at $4.25 million.
• Despite growing popularity, weight loss drugs are seldom being prescribed.
• Voluntary recall of multiple Equate Lubricant Ointments.
• Voluntary recall of TING® 1% Tolnaftate Athlete’s Foot Spray.
• Voluntary recall of one lot of Treprostinil Injection.
• Voluntary Recall of Sustain and Schwinnnng brand.